Most cited papers from Vasopharm (Germany)

Vasopharm (Germany)

What are the most cited papers from Vasopharm (Germany)?

The most cited paper from Vasopharm (Germany) is "The NOX toolbox: validating the role of NADPH oxidases in physiology and disease" (Sebastian Altenhöfer, Pamela W. M. Kleikers, Kim A. Radermacher et al., 2012), with 386 citations. Next come "Novel Nox inhibitor VAS2870 attenuates PDGF-dependent smooth muscle cell chemotaxis, but not proliferation☆" (255) and "Comparative pharmacology of chemically distinct NADPH oxidase inhibitors" (239).

Published TypeFieldAccessCitations

Showing 24 of 24 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	The NOX toolbox: validating the role of NADPH oxidases in physiology and disease Sebastian Altenhöfer, Pamela W. M. Kleikers, Kim A. Radermacher et al. · Cellular and Molecular Life Sciences Open access	30 May 2012	386
2	Novel Nox inhibitor VAS2870 attenuates PDGF-dependent smooth muscle cell chemotaxis, but not proliferation☆ Henrik ten-Freyhaus, Michael Huntgeburth, Kirstin Wingler et al. · Cardiovascular Research Open access	21 Mar 2006	255
3	Comparative pharmacology of chemically distinct NADPH oxidase inhibitors Sven Wind, Knut Beuerlein, Thomas Eucker et al. · British Journal of Pharmacology Open access	17 Jun 2010	239
4	Monitoring of Clopidogrel Action: Comparison of Methods Jörg R. P. Geiger, Lino Lars Teichmann, R. Großmann et al. · Clinical Chemistry	8 Apr 2005	179
5	Novel Nox inhibitor of oxLDL-induced reactive oxygen species formation in human endothelial cells Claudia Stielow, Rusan Ali Catar, Gregor M. Müller et al. · Biochemical and Biophysical Research Communications	30 Mar 2006	125
6	Effects of oral niacin on endothelial dysfunction in patients with coronary artery disease: Results of the randomized, double-blind, placebo-controlled INEF study Ascan Warnholtz, Philipp Sebastian Wild, Mir Abolfazl Ostad et al. · Atherosclerosis	13 Aug 2008	88
7	A single loading dose of clopidogrel causes dose-dependent improvement of endothelial dysfunction in patients with stable coronary artery disease: Results of a double-blind, randomized study Ascan Warnholtz, Mir Abolfazl Ostad, Nathalie Velich et al. · Atherosclerosis	10 Jan 2007	80
8	Angiotensin II induces DNA damage via AT1 receptor and NADPH oxidase isoform Nox4 Gholamreza Fazeli, Helga Stopper, Reinhard Schinzel et al. · Mutagenesis Open access	27 Jul 2012	61
9	The Novel Nitric Oxide Synthase Inhibitor 4-amino-tetrahydro-L-biopterine Prevents Brain Edema Formation and Intracranial Hypertension following Traumatic Brain Injury in Mice Nicole A. Terpolilli, Klaus Zweckberger, Raimund Trabold et al. · Journal of Neurotrauma	Nov 2009	56
10	Who is a ‘healthy subject’?—consensus results on pivotal eligibility criteria for clinical trials Kerstin Breithaupt-Groegler, Christoph Coch, Martin Coenen et al. · European Journal of Clinical Pharmacology Open access	7 Jan 2017	54
11	Nitric Oxide Synthase Inhibition with the Antipterin VAS203 Improves Outcome in Moderate and Severe Traumatic Brain Injury: A Placebo-Controlled Randomized Phase IIa Trial (NOSTRA) John Stover, Antonio Belli, Henry Boret et al. · Journal of Neurotrauma	15 May 2014	54
12	Endothelial Nitric Oxide Synthase Mediates Arteriolar Vasodilatation after Traumatic Brain Injury in Mice Susanne M. Schwarzmaier, Nicole A. Terpolilli, Ari Dienel et al. · Journal of Neurotrauma	3 Nov 2014	35
13	Aldosterone increases kidney tubule cell oxidants through calcium-mediated activation of NADPH oxidase and nitric oxide synthase Nina Queisser, Nicole Schupp, Helga Stopper et al. · Free Radical Biology and Medicine	2 Sep 2011	25
14	Maillard reaction products enriched food extract reduce the expression of myofibroblast phenotype markers Stefanie Ruhs, Norbert Naß, Veronika Somoza et al. · Molecular Nutrition & Food Research	14 Mar 2007	22
15	A cGMP-Dependent Protein Kinase Assay for High Throughput Screening Based on Time-Resolved Fluorescence Resonance Energy Transfer Benjamin Bader, Elke Butt, Alois Palmetshofer et al. · SLAS DISCOVERY Open access	Aug 2001	21
16	Effects of the nitric oxide synthase inhibitor ronopterin (VAS203) on renal function in healthy volunteers Christian Ott, Agnes Bosch, Nicole Winzer et al. · British Journal of Clinical Pharmacology Open access	23 Jan 2019	13
17	A protein phosphorylation-based assay for screening and monitoring of drugs modulating cyclic nucleotide pathways Jörg R. P. Geiger, Tobias Brandmann, Katharina Hubertus et al. · Analytical Biochemistry	13 Aug 2010	13
18	Efficacy of Ronopterin (VAS203) in Patients with Moderate and Severe Traumatic Brain Injury (NOSTRA phase III trial): study protocol of a confirmatory, placebo-controlled, randomised, double blind, multi-centre study on behalf of the NOSTRA Investigators, Frank Tegtmeier, Reinhard Schinzel et al. · Trials Open access	14 Jan 2020	12
19	Tylophorine reduces protein biosynthesis and rapidly decreases cyclin D1, inhibiting vascular smooth muscle cell proliferation in vitro and in organ culture Helge Joa, Tina Blažević, Christoph S. Grojer et al. · Phytomedicine	23 Apr 2019	11
20	Advanced glycation end product accumulation in rho0 cells without a functional respiratory chain Norbert Naß, Alexandra Kukat, Peter Seibel et al. · Biological Chemistry	20 May 2009	7
21	Proteins of Thermus thermophilus Are Resistant to Glycation‐Induced Protein Precipitation: An Evolutionary Adaptation to Life at Extreme Temperatures? Gerald W Münch, Katrin Berbaum, Christin Urban et al. · Annals of the New York Academy of Sciences	Jun 2005	3
22	Nitric Oxide Synthase Inhibitors in Traumatic Brain Injury Reinhard Schinzel, Frank Tegtmeier · Elsevier eBooks Book chapter	7 Oct 2016	2
23	[L-arginine. A key substance for dietetic therapy in arteriosclerosis?]. Kirstin Wingler, Harald H.H.W. Schmidt · PubMed	Mar 2005	1
24	EFFECTS OF THE NO SYNTHASE INHIBITOR RONOPTERIN (VAS203) ON MICRO- AND MACROCIRCULATION IN HEALTHY VOLUNTEERS Claus‐Eric Ott, Agnes Bosch, Susan Jung et al. · Journal of Hypertension	22 Jun 2019	0

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.